GLP-1vsPemvidutide

GLP-1 (glucagon-like peptide 1) is the native incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. It is the endogenous molecule that all GLP-1 receptor agonist drugs (semaglutide, liraglutide, etc.) are designed to mimic. Understanding native GLP-1 is essential to understanding the entire drug class built upon its biology.

Upon release, GLP-1 binds to GLP-1 receptors (GLP-1R) — G protein-coupled receptors expressed on pancreatic beta cells, the GI tract, the heart, the kidneys, and critically, the brain. In the pancreas, GLP-1R activation stimulates adenylyl cyclase, raising intracellular cAMP levels, which potentiates glucose-stimulated insulin secretion. This glucose-dependence is a key safety feature — GLP-1 only promotes insulin release when blood sugar is elevated, minimizing hypoglycemia risk. Simultaneously, GLP-1 suppresses glucagon secretion from alpha cells, further reducing hepatic glucose output.

In the brain, GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate appetite suppression and satiety. GLP-1 also activates vagal afferents to slow gastric emptying, prolonging nutrient absorption and post-meal satiety. The critical limitation of native GLP-1 is its extremely rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids within 1-2 minutes, rendering it inactive. This ultra-short half-life is why pharmaceutical GLP-1 analogues require structural modifications (albumin binding, DPP-4 resistance) to achieve clinically useful durations of action.

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.